CTRI/2019/05/018909已完成2 期
A Phase 2a, Multi-center, Placebo-controlled, Randomized Partially Blinded, Study of Infused METREXASSISTâ?¢ (Parenteral TK-112690) or Metrexassistâ?¢ Placebo Administered Along with Methotrexate Weekly for Four Consecutive Weeks to Patients with Recurrent or Residual SCCHN.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- TOSK INC
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and female subjects over 18 years old with a histologically or cytological confirmed diagnosis of locally residual, recurrent or metastatic SCCHN.
- •Subject must have failed at least onecourses of non-MTX chemotherapy, orone course of non-MTX chemotherapyand chemo radiation for treating their SCCHN.
- •No prior systemic treatments for cancer (chemotherapy and/or radiotherapy) 4 weeks prior to screening.
- •No other concurrent, active, invasive malignancies.
- •An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- •Must have a life expectancy of at least 6 months.
- •History of brain metastases allowed if disease has stabilized or improved after radiation and/or craniotomy.
- •No active angina or uncontrolled arrhythmia.
- •No detectable infection including hepatitis B/C and HIV.
- •Not pregnant or nursing. Women of childbearing potential must have a negative urine pregnancy test at screening and on the day before dosing and must use medically acceptable methods of birth control. Acceptable methods of birth control include oral or transdermal contraceptives, condoms, spermicidal foam, IUD, progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or post-menopausal for >= 1 year, must be specified in the patientâ??s medical history file and CRF.
- •Must have adequate organ and immune function as indicated by the following laboratory values:
- •Parameter Laboratory Values
- •Serum creatinine <=1.5 x ULN
- •Est. creatinine clearance >=45 mL/min
- •Total bilirubin<=2.0 mg/dL (<=34.2 μmol/L)
- •AST & ALT <=3 x ULN
- •Absolute granulocytes >=1.5 x 109 cells/L
- •Platelets >=100,000/µL
- •Be able to read orunderstand, and provide a signature or thumb impression on the Informed Consent Form (ICF) before entering the study.
排除标准
- •Subject has not failed at least onecourses of non-MTX chemotherapyor one course of non-MTX chemotherapy and chemo radiation for treating their SCCHN.
- •Uncontrolled active infection.
- •Current mucositis ( >Grade 1).
- •Pregnant or nursing mother.
- •Prior history of a cerebrovascular accident or hemorrhage.
- •Congestive heart failure, as defined by New York Heart Association class III or IV.
- •Uncontrolled hypertension.
- •Active psychiatric/mental illness making informed consent or useful clinical follow-up unlikely.
- •Subjects who have previously been enrolled into this study and subsequently withdrew.
- •Subject receiving other investigational agent(s).
- •Any systemic immunosuppressive medication/therapy (eg, other chemotherapy, steroids).
- •Any significant systemic illness, unstable or severe medical condition(s) that could put the subject at risk during the study, interfere with outcome measures, or affect compliance with the protocol procedures such as intercurrent infection and/or autoimmune disease, ie, any condition that compromises the immune system.
- •Known or suspected intolerance or hypersensitivity to the study materials (TK-112690 and/or excipients or closely related compounds).
- •Subjects, who have received, or plan to receive, radiation or chemotherapy within 4 weeks of screening.
- •Subjects that have a history of poor compliance in clinical research studies.
- •Subjects that have participated in any other investigative clinical trial in the past 4 weeks.
研究者
相似试验
已完成
2 期
A study to evaluate the safety and efficacy of test product TK-90 or placebo in Head and Neck cancer patients receiving radiotherapy.CTRI/2022/06/043203Tosk Inc24
已完成
2 期
A clinical study to access safety and efficacy of TK-90 or parenteral TK-90 placebo in patients with colorectal cancer scheduled to receive bolus 5-fluorouracil and infused leucovorin.CTRI/2022/06/043202Tosk Inc24
已完成
2 期
A study of the safety of 3 months treatment with BIT225, in combination with pegylated interferon and ribavirin, in patients with chronic hepatitis C infection, compared to pegylated interferon and ribavirin alone, including measurement of the concentration of BIT225 in the blood and antiviral activity.Hepatitis C Virus InfectionInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12613001296729Biotron Limited60
进行中（未招募）
1 期
A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV doses of Bermekimab for the Treatment of Adult Participants with Moderate-to-Severe Atopic DermatitisModerate to Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-005900-21-DEJanssen-Cilag International NV60
招募中
1 期
A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosisoncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver FibrosisMedDRA version: 24.1Level: LLTClassification code: 10086370Term: NASH with fibrosis Class: 100000004848CTIS2023-508104-38-00Kowa Research Institute Inc.300